Evidence map›Paper›PMID 26496694›Full record

ArticlePLoS pathogens2015

Identification of a Novel Lipoprotein Regulator of Clostridium difficile Spore Germination.

Kelly A Fimlaid, Owen Jensen, M Lauren Donnelly, Michael B Francis, Joseph A Sorg, Aimee Shen

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 76 citations in OpenAlex.

  1. A programmed reset mechanism primesScience advances · 2026
    Article
  2. Review
  3. Article
  4. Unique growth and morphology properties of Clade 5bioRxiv : the preprint server for biology · 2025
    Article
  5. Article
  6. Review
  7. Clinical microbiology reviews · 2024
    Review
  8. Clostridioides difficile Sporulation.Advances in experimental medicine and biology · 2024
    Review
  9. Article
  10. Article
  11. A dual-action antibiotic that killsProceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Opportunities for Nanomedicine inAntibiotics (Basel, Switzerland) · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kelly A FimlaidDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, United States of America; Program in Cellular, Molecular & Biomedical Sciences, University of Vermont, Burlington, Vermont, United States of America.
Owen JensenDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, United States of America.
M Lauren DonnellyDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, United States of America.
Michael B FrancisDepartment of Biology, Texas A&M University, College Station, Texas, United States of America.
Joseph A SorgDepartment of Biology, Texas A&M University, College Station, Texas, United States of America.
Aimee ShenDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, United States of America.
University of Vermont · USTexas A&M University · US

Funding

Vermont Immunobioloigy/ Infectious Diseases CenterP20GM103496 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI BUDD, RALPH C · 2012 to 2015
$8.7M
Mechanisms of Clostridium difficile spore germinationR01AI116895 · NIAID · TEXAS A&M UNIVERSITY · PI SORG, JOE · 2015 to 2024
$3.9M
Regulation of Spore Germination in Clostridioides difficileR01GM108684 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Aimee Shen · 2014 to 2026
$3.0M
Vermont Immunology/Infectious Diseases Training GrantT32AI055402 · NIAID · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI GARY E WARD · 2005 to 2026
$2.7M
NIAID NIH HHS R01 AI116895NIAID NIH HHS T32 AI055402NIGMS NIH HHS P20 GM103496NIGMS NIH HHS R01 GM108684NIGMS NIH HHS R01GM108684
6 · The paper itself

Abstract

Clostridium difficile is a Gram-positive spore-forming pathogen and a leading cause of nosocomial diarrhea. C. difficile infections are transmitted when ingested spores germinate in the gastrointestinal tract and transform into vegetative cells. Germination begins when the germinant receptor CspC detects bile salts in the gut. CspC is a subtilisin-like serine pseudoprotease that activates the related CspB serine protease through an unknown mechanism. Activated CspB cleaves the pro-SleC zymogen, which allows the activated SleC cortex hydrolase to degrade the protective cortex layer. While these regulators are essential for C. difficile spores to outgrow and form toxin-secreting vegetative cells, the mechanisms controlling their function have only been partially characterized. In this study, we identify the lipoprotein GerS as a novel regulator of C. difficile spore germination using targeted mutagenesis. A gerS mutant has a severe germination defect and fails to degrade cortex even though it processes SleC at wildtype levels. Using complementation analyses, we demonstrate that GerS secretion, but not lipidation, is necessary for GerS to activate SleC. Importantly, loss of GerS attenuates the virulence of C. difficile in a hamster model of infection. Since GerS appears to be conserved exclusively in related Peptostreptococcaeace family members, our results contribute to a growing body of work indicating that C. difficile has evolved distinct mechanisms for controlling the exit from dormancy relative to B. subtilis and other spore-forming organisms.

Indexed as

AnimalsBacterial ProteinsCarrier ProteinsClostridioides difficileCricetinaeLipoproteinsSpores, BacterialBacterial ProteinsCarrier Proteinscold-shock protein CspB, BacteriaCspC protein, ClostridiumLipoproteins

Identifiers

PMID26496694
PMCPMC4619724
OpenAlexW2166520113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.